Cargando…

PB2328: CHRONIC LYMPHATIC LEUKAEMIA (CLL) ASSOCIATED TO ACQUIRED FACTOR V INHIBITOR. A CASE REPORT.

Detalles Bibliográficos
Autores principales:	Porro Camarero, A., Hernandez de Castro, I., Iglesias, J. C., López de Ugarriza, P., Rodríguez de Miñón, C., Flórez Meana, G., Alonso Álvarez, S., Bernardo Gutiérrez, Á., Soto Ortega, I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429086/ http://dx.doi.org/10.1097/01.HS9.0000852136.48587.07

Ejemplares similares

PB2327: BONE MARROW STUDY IN THROMBOPENIA
por: López De Ugarriza, P., et al.
Publicado: (2022)

PB1952: CLL IN AYA
por: Mohamed, Shehab, et al.
Publicado: (2023)

PB1911: CYTOGENOMIC INTEGRATIVE ANALYSIS OF CLL/SLL PATIENTS AT DISEASE PROGRESSION.
por: García-Serra, Rocío, et al.
Publicado: (2023)

PB1867: PURINE ANALOGS ON HAIRY CELL LEUKAEMIA TREATMENT
por: Gomes, G., et al.
Publicado: (2022)

PB1950: CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): REAL-WORLD DATA FROM LEBANON
por: Nasr, Lewis, et al.
Publicado: (2023)

PB2328: TRIAL IN PROGRESS: ATHENA-1 – A PHASE 1 STUDY TO ASSESS SAFETY AND TOLERABILITY OF REGN5837 IN COMBINATION WITH ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA
por: Mutsaers, Pim G. N. J., et al.
Publicado: (2023)

PB1945: PATIENT PERSPECTIVES ON CLL TREATMENT SIDE EFFECTS: A SUB-ANALYSIS OF THE VOICE SURVEY
por: Tam, Constantine, et al.
Publicado: (2023)

PB1958: IBRUTINIB AS THIRD LINE THERAPY IN CLL PATIENTS, A 5-YEAR STUDY IN ALBANIA
por: Qerama, Shaqir, et al.
Publicado: (2023)

PB1859: DEFINING T-CELL POPULATIONS IN CHRONIC LYMPHOCYTIC LEUKAEMIA
por: Mora, A., et al.
Publicado: (2022)

PB2353: HEALTHCARE RESOURCE UTILIZATION AND COSTS OFF THERAPY WITH FIXED-DURATION VENETOCLAX AMONG CLL PATIENTS
por: Allan, J. N., et al.
Publicado: (2022)

PB1936: IDENTIFYING INEQUITIES IN SUPPORT - GLOBAL SURVEY OF PATIENT ORGANISATIONS DELIVERING SUPPORT SERVICES FOR CLL PATIENTS
por: Baker, Deborah, et al.
Publicado: (2023)

PB1923: NON-HEMATOLOGIC AUTOIMMUNE DISORDERS IN CLL: PREVALENCE AND PROGNOSTIC IMPACT IN A REAL-LIFE COHORT FROM A SINGLE-CENTRE
por: De Tomás, Miguel Argüello, et al.
Publicado: (2023)

PB1866: RESPONSE TO NOVEL ANTI CD20 ANTIBODY AND BCL2 INHIBITOR IN A PATIENT WITH CLL AND MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS ASSOCIATED WITH LEUKEMIC KIDNEY INFILTRATION AND REVIEW OF LITERATURE
por: Goanta, J. G., et al.
Publicado: (2022)

PB1864: BRUIN CLL-321: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS INVESTIGATOR’S CHOICE OF IDELALISIB+RITUXIMAB OR BENDAMUSTINE+RITUXIMAB IN BTKI PRETREATED CLL/SLL (TRIAL IN PROGRESS)
por: Sharman, J. P., et al.
Publicado: (2022)

PB1863: BRUIN CLL-322: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB+VENETOCLAX AND RITUXIMAB VS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CLL/SLL (TRIAL IN PROGRESS)
por: Mato, A. R., et al.
Publicado: (2022)

PB1909: LOW-BURDEN TP53 MUTATIONS REPRESENT FREQUENT GENETIC EVENTS IN CLL WITH AN INCREASED RISK FOR TREATMENT INITIATION
por: László, Tamás, et al.
Publicado: (2023)

PB1931: LOW SERUM CHOLESTEROL LEVEL AS A SIGNIFICANT PROGNOSTIC FACTOR IMPROVES CLL-IPI IN CHRONIC LYMPHOCYTIC LEUKEMIA
por: Gao, Rui, et al.
Publicado: (2023)

Immune Response to Covid-19 Vaccination in Patients with Chronic Lymphocytic Leukaemia (CLL): An Experience from Two Italian Centres
por: Innocenti, Idanna, et al.
Publicado: (2022)

PB1779: DEVELOPING NOVEL SYNERGISTIC DRUG COMBINATIONS WITH VENETOCLAX IN ACUTE MYELOID LEUKAEMIA
por: Harrigan, R., et al.
Publicado: (2022)

PB1901: KARYOTYPIC PROFILE OF CHRONIC MYELOID LEUKAEMIA DIAGNOSED AT TERTIARY LEVEL IN AFGHANISTAN.
por: Haidary, A. M., et al.
Publicado: (2022)

PB1921: IS CHEMOIMMUNOTHERAPY (CIT) HISTORY IN THE FIRST LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKAEMIA?
por: Parbutt, Catherine, et al.
Publicado: (2023)

PB1881: IBRUTINIB REDUCES THE RISK OF RICHTER’S TRANSFORMATION IN PREVIOUSLY TREATED CLL PATIENTS: A POPULATION-BASED STUDY IN BRITISH COLUMBIA
por: Ramadan, R., et al.
Publicado: (2022)

PB2309: EVALUATION OF MORBIMORTALITY FACTORS OF PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA
por: Pinto, M. I., et al.
Publicado: (2022)

PB2278: ACQUIRED ANGIOEDEMA ASSOCIATED WITH LYMPHOPROLIFERATIVE DISORDERS: A CASE SERIES
por: Ng, Jun Yen, et al.
Publicado: (2023)

PB1940: REAL-LIFE EXPERIENCE OF THE IMMUNE RECONSTITUTION IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA AND SMALL LYMPHOCYTIC LYMPHOMA TREATED WITH IBRUTINIB.
por: Pérez, Belén Olivares, et al.
Publicado: (2023)

PB1820: THE EFFECT OF CONVENTIONAL CHEMOTHERAPY AFTER EXITING QUIESCENT STATE IN ACUTE MYELOID LEUKAEMIA
por: Láinez-González, Daniel, et al.
Publicado: (2023)

PB1973: MOLECULAR PATTERNS OF RESPONSE AFTER FRONTLINE TREATMENT IN CHRONIC MYELOID LEUKAEMIA (CML).
por: Fernandez-Leyva, Harberth
Publicado: (2023)

PB1938: REAL WORLD EFFECTIVENESS AND SAFETY OF VENETOCLAX IN COMBINATION WITH OBINUTUZUMAB IN TREATMENT NAIVE CLL PATIENTS – DATA FROM THE OBSERVATIONAL STUDY VERVE
por: Schwaner, Ingo, et al.
Publicado: (2023)

PB2323: ACQUIRED HEMOPHILIA: A CASE REPORT
por: Haddad, N., et al.
Publicado: (2022)

PB1934: MEASURED OPTIMUM ANTI-SPIKE LEVEL VACCINATION STRATEGY AND ANTI-VIRAL ACCESS RESULT IN LOW COVID HOSPITALISATION AND MORTALITY IN CLL AND MBL
por: Shen, Yandong, et al.
Publicado: (2023)

PB1756: EPIDEMIOLOGY OF ACUTE LYMPHOBLASTIC LEUKAEMIA: A RETROSPECTIVE 6-YEAR SINGLE CENTRE EXPERIENCE
por: Kociaj, Jora, et al.
Publicado: (2023)

PB2329: ACQUIRED HEMOPHILIA-POTENTIALLY FATAL IF NOT TREATED PROMPTLY
por: Stankovikj, S., et al.
Publicado: (2022)

PB1872: ANTIBODY RESPONSES AFTER COVID-19 VACCINATION IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA, EITHER TREATED OR NAÏVE. A MONOCENTRIC EXPERIENCE.
por: Innocenti, I., et al.
Publicado: (2022)

PB1899: OUTCOMES OF PATIENTS UNDERGOING TREATMENT FOR ACUTE MYELOID LEUKAEMIA SHOWING HIGH DEGREE OF PREDICTIVE ACCURACY ON THE EUROPEAN LEUKAEMIA NET (ELN) POST-REMISSION TREATMENT SCORE
por: Richardson, Michelle, et al.
Publicado: (2023)

PB2319: ACQUIRED COAGULOPATHY: FACTOR X DEFICIENCY AT DIAGNOSIS OF MULTIPLE MYELOMA WITHOUT ASSOCIATED AMYLOIDOSIS
por: De La Torre De La Paz, M., et al.
Publicado: (2022)

PB1940: ACQUIRED APLASTIC ANEMIA: THE CHALLENGE OF TREATMENT IN MEXICO. SINGLE HEMATOLOGY CENTER EXPERIENCE
por: Guajardo Leal, M. L., et al.
Publicado: (2022)

PB1854: NEXT GENERATION SEQUENCING APPROACHES IN CHRONIC LYMPHOCYTIC LEUKAEMIA: FINDINGS FROM EXTERNAL QUALITY ASSESSMENT
por: Cartwright, A., et al.
Publicado: (2022)

PB1827: TWO-LEVEL INHIBITION OF HEDGEHOG SIGNALLING PATHWAY TO EXIT QUIESCENT STATE IN ACUTE MYELOID LEUKAEMIA
por: Láinez-González, Daniel, et al.
Publicado: (2023)

PB1949: ROLE OF LAIR1 (CD305) IN FLOW CYTOMETRIC DETECTION OF OCCULT BONE MARROW INVOLVEMENT IN NON-CLL B-CELL NON-HODGKIN LYMPHOMA
por: Ghogale, Sitaram, et al.
Publicado: (2023)

PB1960: SARS-COV-2 OMICRON VARIANT INFECTION AND COVID-19 IN PERSONS WITH CHRONIC MYELOID LEUKAEMIA IN CHINA
por: Cheng, Fang, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_o37lgecjj4o39jr68rrhn8jv5r